Board Elects Marvyn Robar as First Independent, Non-Executive Chairman
HALIFAX, May 6, 2014 /CNW/ - MedMira Inc. (TSXV: MIR) announced today that its Board of Directors appointed Marvyn Robar and Colin MacGillivray as Directors to serve until the next annual shareholder meeting. Dr. Shou-Ching Tang retired from the Board of Directors after 12 years of service. The Board thanks Dr. Tang for his services and the guidance he provided to MedMira during his tenure as a member of the Board. These changes were effective May 2, 2014.
The Board elected Mr. Robar as the Company's first non-executive Chairman. Hermes Chan, CEO of MedMira, who served as interim Chairman, will remain as the member of the Board. The appointment of Mr. Robar, supports the Board's commitment to the advancement of MedMira's corporate governance practices and policies and enables the implementation of industry best practices within the Company.
"The diverse industry experience and backgrounds of both our new Chairman and new director complements the expertise of our other Board members. Being able to engage such respected independent directors further aligns us with industry best practices in corporate governance and positions us well to build upon our successes," said Hermes Chan, CEO, MedMira.
Mr. Robar brings extensive experience to the role of Chairman of Board with over 35 years in both the private and public sectors. Prior to his retirement from the Government of Nova Scotia 2013, Mr. Robar served as the Vice President, Investment, Department of Economic and Rural Development and Tourism, in charge of the $700 million economic development fund and as President of the Nova Scotia Strategic Opportunities Fund Inc., a $250 million investment fund. In this role, Mr. Robar had the opportunity to work with many of Nova Scotia's largest companies as well as a range of small and medium sized enterprises. He routinely provided advice and recommendations to the Executive Council of the Province of Nova Scotia, ministers, and deputy ministers across a broad range of departments on files and portfolios. After completing a BSc in chemistry/math and working as a chemist at the Nova Scotia Research Foundation, Mr. Robar returned to Dalhousie University, obtained an MBA and subsequently, went on to join PricewaterhouseCoopers and earn his Chartered Accountancy designation.
"I look forward to working closely with other experienced Board members, Hermes, and his management team as we continue the Company's focus on innovation and revenue generation," said Marvyn Robar, Chairman of MedMira. "MedMira is a company that is reinventing the rapid diagnostics sector with its distinct technology and the Board is fully committed to guiding this Company forward and delivering on its promise of increasing shareholder value through strategic growth."
The Board also appointed Colin MacGillivray as a Director. Dr. MacGillivray has over 20 years of experience including finance and operating experience in life sciences across multiple geographies with Elan Pharmaceuticals Inc., Lundbeck Inc. (the US subsidiary of H. Lundbeck A/S, Denmark) and Biolytical Laboratories, along with broader experience from a range of other industries. Dr. MacGillivray is a Member of the Institute of Chartered Accountants in England & Wales having qualified with PricewaterhouseCoopers. He received his Ph.D. from the Department of Animal & Plant Sciences, University of Sheffield following undergraduate studies at the University of Edinburgh.
MedMira is a leading developer and manufacturer of vertical flow rapid diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal®, Multiplo™ and Miriad™ brands in global markets. Based on its patented Rapid Vertical Flow Technology™, MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: MedMira Inc.
For further information:
Andrea Young, Corporate Communications